Open Innovation: The Fast-Track To Global Pharma Power For Korea?
Executive Summary
Although South Korea has a good clinical trial infrastructure, workforce, and novel drug development technology, it still lacks the power to lead the development of new drugs across the finish line. The country needs to create an environment that can attract multinationals to co-research and co-develop drugs with domestic pharma firms under open innovation programs if Korea-originated blockbusters are ever to emerge, experts told a recent forum in Seoul.
You may also be interested in...
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.